Whole-body MRI finds breast cancer metastases earlier

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Whole-body MRI should be the go-to imaging modality for detecting bone metastases in asymptomatic patients.

SAN DIEGO-Whole-body MRI should be the go-to imaging modality for detecting bone metastases in asymptomatic patients, according to a study presented at the 2010 American Roentgen Ray Society meeting.

Joshita Singh, MD, and colleagues at Deenanath Mangeshkar Hospital and Research Center in Pune, India, included 99 patients with known breast cancer.

"Of the 99 patients, MRI accurately revealed that 47 patients were positive for metastases while 52 were negative. Of those patients who were positive for metastases, whole-body MRI frequently detected bone metastases earlier when the patient was still asymptomatic," Dr. Singh said (abstract 194).

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content